Non-high-density lipoprotein cholesterol: A target of lipid-lowering in dialysis patients

American Journal of Kidney Diseases

Volumn 41, Issue 3 SUPPL. 1, 2003, Pages

  Wanner, Christoph ^a,b   Krane, Vera ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

3 Hydroxy 3 methylglutaryl coenzyme A (HMG CoA) reductase inhibitors; Hemodialysis (HD); Intermediate density lipoprotein (IDL) cholesterol (IDL C); Remnants; low density lipoprotein cholesterol (LDL C)

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTILIPEMIC AGENT; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

CONFERENCE PAPER; DRUG EFFICACY; DRUG TARGETING; DYSLIPIDEMIA; HEART INFARCTION; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; MORTALITY; PRACTICE GUIDELINE; TREATMENT PLANNING; UREMIA;

EID: 0037373839     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2003.50089     Document Type: Conference Paper

References (21)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
2. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D: Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 15:1300-1331, 1994
3. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21:573-592, 1993
4. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: Atherogenic lipoprotein phenotype in end-stage renal failure: Origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 35:852-862, 2000
5. Hirany S, O'Byrne D, Devaraj S, Jialal I: Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease. Clin Chem 46:667-672, 2000
6. Shoji T, Nishizawa Y, Kawagishi T, et al: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9:1277-1284, 1998
7. Stampfer MJ, Krauss RM, Ma J, et al: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882-888, 1996
8. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B: The metabolic syndrome, LDL particle size, and atherosclerosis: The Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 20:2140-2147, 2000
9. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 282:2340-2346, 1999
10. Stein DT, Devaraj S, Balis D, Adams-Huet B, Jialal I: Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol 21:2026-2031, 2001
11. Shoji T, Kawagishi T, Emoto M, et al: Additive impacts of diabetes and renal failure on carotid atherosclerosis. Atherosclerosis 153:257-258, 2000
12. Hodis HN: Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 99:2852-2854, 1999
13. Byrne CD: Triglyceride-rich lipoproteins: Are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype? Atherosclerosis 145:1-15, 1999
14. Pedro BJ, Senti M, Rubies PJ, Pelegri A, Romero R: When to treat dyslipidaemia of patients with chronic renal failure on haemodialysis? A need to define specific guidelines. Nephrol Dial Transplant 11:308-313, 1996
15. Wanner C, Hörl WH, Luley CH, Wieland H: Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 39:754-760, 1991
16. Nishizawa Y, Shoji T, Emoto M, et al: Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin Nephrol 43:268-277, 1995
17. Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y: Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis 38:S30-S33, 2001 (suppl 1)
18. Saltissi D, Morgan C, Rigby RJ, Westhyzen J: Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 39:282-290, 2002
19. Wanner C, Krane V, Ruf G, März W, Ritz E: Rationale and design of a trial improving outcome of type 2 diabetes on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 71:S222-S226, 1999
20. Karpe F, Taskinen M, Nieminen MS, et al: RLP cholesterol concentration and progression of coronary and vein graft atherosclerosis in response to gemfibrozil treatment. Atherosclerosis 157:181-187, 2001
21. Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999